ObsEva SA: ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: